Trial Profile
Evaluation of MEpolizumab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs Azathioprine (Primary) ; Cyclophosphamide (Primary) ; Mepolizumab (Primary) ; Prednisone
- Indications Granulomatosis with polyangiitis
- Focus Therapeutic Use
- Acronyms E-merge
- 28 Jun 2022 Planned End Date changed from 1 Dec 2024 to 1 May 2025.
- 28 Jun 2022 Planned primary completion date changed from 1 Dec 2024 to 1 May 2025.
- 28 Jun 2022 Status changed from not yet recruiting to recruiting.